Caris Life Sciences Appoints Brian Lamon, Ph.D., as Chief Business Officer, Head of BioPharma Business Development
IRVING, Texas, Oct. 6, 2020 /PRNewswire/ — Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian Lamon, Ph.D., has been appointed Chief Business Officer, Head of BioPharma Business Development.
In this role, Lamon will be responsible for developing the partnering and business development strategy for the company and translating that strategy into actionable and achievable goals for the broader Caris organization.
“We are very excited to welcome Brian to Caris,” said Brian J. Brille, Vice Chairman of Caris Life Sciences. “His expertise in oncology clinical development, business development, translational medicine and medical affairs, and track record of maximizing value from external relationships will further advance our business development strategies to position the company for continued growth.”
Lamon brings over 15 years of experience from large pharma and academia to Caris. He previously worked for Bristol Myers